Report scope. This 2026 Drug Asset Due Diligence Report evaluates NG-350A as a potential licensing, partnership, acquisition, or option asset. The review separates verified evidence from open diligence questions across clinical development, intellectual property, market positioning, and transaction precedent.
Executive recommendation: HOLD / OPTION
NG-350A is a Gene therapy associated with CD40 and a global highest development stage of Phase 1. The lead disclosed indication is Locally Advanced Rectal Carcinoma. The current evidence supports a HOLD / OPTION posture, subject to confirmation of study-level data, ownership, patent coverage, manufacturing readiness, and regional rights.
Decision memo
- Asset: NG-350A
- Target: CD40
- Lead indication: Locally Advanced Rectal Carcinoma
- Highest phase: Phase 1
- Matched trials: 3
- Matched result records: 3
- Matched asset deals: 3
Use PatSnap Life Sciences MCP servers to validate the NG-350A diligence evidence.
1. Asset identity and development status
The first diligence task is entity resolution. Teams should reconcile development codes, nonproprietary names, salts, formulations, combinations, sponsors, and predecessor owners before relying on portfolio counts. For NG-350A, the MCP profile identifies CD40 as the primary target context and Locally Advanced Rectal Carcinoma as the lead indication. Global phase labels are useful orientation points, but investment decisions require country- and indication-level status verification.
Confirm the exact molecule, formulation, route, dose, biomarker definition, and current sponsor. Review discontinuations separately from active development so that an historical high phase is not mistaken for a live program.
Use PatSnap Life Sciences MCP servers to validate the NG-350A diligence evidence.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06459869 | Phase 1 | Active, not recruiting | 30 | Not disclosed |
| NCT05165433 | Phase 1 | Completed | 14 | Not disclosed |
| NCT03852511 | Phase 1 | Completed | 28 | Not disclosed |
The clinical program should be audited for randomization, comparator relevance, dose selection, endpoint hierarchy, multiplicity, analysis population, geographic mix, and readout timing. Early-stage programs require attention to pharmacokinetics, pharmacodynamics, adverse events, dose-limiting toxicities, and the rationale for the expansion dose.
Use PatSnap Life Sciences MCP servers to validate the NG-350A diligence evidence.
3. Clinical readouts: what is known
First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments
Study: NCT03852511 | NCT05165433 | NCT06459869 (phase Ia/Ib study, Pubmed | J Immunother Cancer). Phase: Phase 1. Enrollment: 25. Published: 2024-10-01.
Inflammatory cytokines = sustained increases, particularly with higher intravenous dose levels | Inflammatory cytokines = sustained increases, particularly with higher intravenous dose levels
FORTITUDE: Results of a phase 1a study of the novel transgene-armed and tumor-selective vector NG-350A with and without pembrolizumab (pembro).
Study: NCT03852511 (FORTITUDE, ASCO2022). Phase: Phase 1. Enrollment: 28. Published: 2022-06-02.
SAE = No systemic CD40 transgene protein was detected at any dose level and the only SAE to occur in >1 pt was pneumonia. | SAE = No systemic CD40 transgene protein was detected at any dose level and the only SAE to occur in >1 pt was pneumonia.
1011P FORTITUDE phase I study of NG-350A, a novel tumour-selective adenoviral vector expressing an anti-CD40 agonist antibody: Monotherapy dose escalation results
Study: NCT03852511 (FORTITUDE, ESMO2021). Phase: Phase 1. Enrollment: 16. Published: 2021-09-16.
AE = well-tolerated, with no cases of Grade≥3 CRS nor evidence of raised liver enzymes
For every reported endpoint, obtain the protocol, statistical analysis plan, patient disposition, baseline characteristics, subgroup definitions, exposure duration, and full safety tables. Conference abstracts and registry summaries can support screening, but they should not replace source data review in a binding transaction.
Use PatSnap Life Sciences MCP servers to validate the NG-350A diligence evidence.
4. Market and competitive position
The commercial case depends on differentiated efficacy, tolerability, convenience, biomarker reach, treatment setting, and access. A target-level market may be attractive while an individual asset remains undifferentiated. Benchmark NG-350A against approved therapies and clinical competitors in Locally Advanced Rectal Carcinoma, including likely standards of care at the expected launch date.
Build a scenario model around addressable patients, diagnosis and biomarker rates, line of therapy, duration, net price, uptake, displacement, combination costs, and probability-adjusted timelines. Test slower enrollment, delayed readout, narrower labels, safety restrictions, and competitor launches.
Use PatSnap Life Sciences MCP servers to validate the NG-350A diligence evidence.
5. Transaction precedent and economics
| Date | Transaction | Status | Type | Disclosed value |
|---|---|---|---|---|
| 2024-12-17 | Akamis Bio Enters Into Licensing Agreement Granting Xuanzhu Biopharma the Greater China Region Rights for NG-350A | Active | License | Not disclosed |
| 2023-02-16 | Akamis Bio, Parker Institute for Cancer Immunotherapy, and Cancer Research Institute Announce Expanded Partnership to Advance Novel Treatments for Pancreatic Cancer | Active | Collaboration | Not disclosed |
| 2018-11-15 | PsiOxus Therapeutics to Collaborate with the Parker Institute for Cancer Immunotherapy on Virus-Based Gene Therapy to Treat Solid Tumors | Active | Collaboration | Not disclosed |
Transaction records should be normalized for territory, asset scope, phase at signing, option mechanics, development obligations, cost sharing, royalties, milestones, and change-of-control terms. Undisclosed economics must not be converted into invented benchmarks.
6. IP and freedom-to-operate screen
Complete a family-level patent review covering composition of matter, sequence or construct claims, polymorph and salt claims, formulation, dosing, combinations, biomarkers, manufacturing, and method of use. Verify priority, ownership, assignments, prosecution status, term adjustments, extensions, oppositions, and regional coverage. Freedom to operate is a separate legal analysis and should include competitor claims and platform dependencies.
The diligence room should reconcile inventorship, employee and contractor assignments, university or platform licenses, sublicensing restrictions, government rights, and obligations triggered by development milestones or commercialization.
Use PatSnap Life Sciences MCP servers to validate the NG-350A diligence evidence.
7. Principal risks and diligence gates
- Identity risk: resolve all aliases, formulations, combinations, and owners.
- Clinical risk: confirm source data, protocol deviations, endpoint definitions, and safety follow-up.
- Regulatory risk: review agency correspondence, meeting minutes, holds, commitments, and indication-specific pathways.
- IP risk: validate enforceable coverage, remaining life, ownership, and freedom to operate.
- CMC risk: assess process control, analytical methods, comparability, scale-up, supply, and cost of goods.
- Commercial risk: pressure-test differentiation, market access, competitive timing, and realistic adoption.
- Transaction risk: map rights, encumbrances, royalties, options, consent requirements, and change-of-control provisions.
8. Final go/no-go memorandum
HOLD / OPTION
Proceed only through staged diligence. Before exclusivity or a binding offer, require a verified asset identity package, complete clinical data room, regulatory correspondence, patent-family schedule, freedom-to-operate opinion, CMC package, ownership chain, regional rights map, and risk-adjusted valuation. Any material mismatch between public records and source documents should pause the process until reconciled.
Method note: This report uses PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP data retrieved on 2026-10-15. It is a screening and diligence framework, not medical, legal, regulatory, or investment advice.
